نتائج البحث - "Ruediger Hehlmann"

المساهمون: Hehlmann, R, Cortes, J, Zyczynski, T, Gambacorti-Passerini, C, Goldberg, S, Mauro, M, Michallet, M, Simonsson, B, Williams, L, Gajavelli, S, Degutis, I, Sen, G, Paquette, R

المصدر: American Journal of Hematology

مصطلحات موضوعية: Male, medicine.medical_specialty, Myeloid, medicine.drug_class, Respiratory Tract Diseases, Dasatinib, Antineoplastic Agents, Drug Administration Schedule, Tyrosine-kinase inhibitor, 03 medical and health sciences, 0302 clinical medicine, Intolerances, MED/15 - MALATTIE DEL SANGUE, Internal medicine, Humans, Medicine, Molecular Targeted Therapy, Musculoskeletal Diseases, Prospective Studies, Hematologi, Prospective cohort study, Protein Kinase Inhibitors, Research Articles, Aged, Cancer och onkologi, Drug Substitution, business.industry, Disease Management, Myeloid leukemia, Imatinib, Hematology, Hematologic Diseases, United States, respiratory tract diseases, Europe, Pyrimidines, medicine.anatomical_structure, Nilotinib, Drug Resistance, Neoplasm, Cancer and Oncology, 030220 oncology & carcinogenesis, Leukemia, Myeloid, Chronic-Phase, Imatinib Mesylate, Female, business, Research Article, 030215 immunology, medicine.drug

وصف الملف: application/pdf; ELETTRONICO

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf757800bc84051386bb54526e10caf5
https://doi.org/10.1002/ajh.25306

View record at Wiley

5

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

المساهمون: Hochhaus A., Baccarani M., Silver R.T., Schiffer C., Apperley J.F., Cervantes F., Clark R.E., Cortes J.E., Deininger M.W., Guilhot F., Hjorth-Hansen H., Hughes T.P., Janssen J.J.W.M., Kantarjian H.M., Kim D.W., Larson R.A., Lipton J.H., Mahon F.X., Mayer J., Nicolini F., Niederwieser D., Pane F., Radich J.P., Rea D., Richter J., Rosti G., Rousselot P., Saglio G., Saussele S., Soverini S., Steegmann J.L., Turkina A., Zaritskey A., Hehlmann R., Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., Nicolini, F., Niederwieser, D., Pane, F., Radich, J. P., Rea, D., Richter, J., Rosti, G., Rousselot, P., Saglio, G., Saussele, S., Soverini, S., Steegmann, J. L., Turkina, A., Zaritskey, A., Hehlmann, R., Centre hospitalier universitaire de Poitiers (CHU Poitiers), Institut Bergonié [Bordeaux], UNICANCER, Centre Léon Bérard [Lyon], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Infection et inflammation (2I), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Novartis Berlin Mathematical School, BMS Daiichi-Sankyo Janssen Pharmaceuticals Angelini Pharma Pfizer, The ELN panel for recommendations in CML comprises 34 experts from Europe, America, and the Asian-Pacific areas. The panel met six times at international meetings of the American Society of Hematology (2015, 2016), the European School of Hematology (2017), the ELN (2019), the European Investigators on CML (2019), and the European School of Hematology/International CML Foundation (2019). Five sets of key questions were submitted to panel members to complement the meetings. Discordant opinions were harmonized by email discussions, and a consensus of 75–100% was reached in most, but not all instances. Unresolved controversies are described in the discussion section. The costs of the meetings and the preparation of the interim and final reports were born entirely by ELN, a research network of excellence initiated by the European Union, now funded by donations and projects of ELN participants. There was no financial support from industry for any activity. Treatment recommendations are limited to the TKIs that have been approved with at least one indication in CML, either by the US Federal Drug Administration (FDA) or/and by the European Medicine Agency (EMA). The drugs are listed in the order of FDA approval. The panel acknowledges that not all drugs may be available worldwide and that the high price of some makes access to these drugs problematic in some countries., Conflict of interest Members of the expert panel declare the following potential conflicts of interest: AH, Research support: Novartis, BMS, MSD, Pfizer, Incyte. Honoraria: Novartis, BMS, Pfizer, Incyte, Takeda, Fusion Pharma. MB, Honoraria: Novartis, BMS, Pfizer, Incyte, Ariad, Takeda, Fusion Pharma. Logistic support: Novartis, BMS, Pfizer, Incyte, Ariad. CS, Research support: Ariad. Honoraria: Novartis, Teva, Pfizer, Juno, Astellas, Ambit. JFA, Research support: Incyte, Novartis, Pfizer. Honoraria: Incyte, Novartis, Pfizer, BMS. FC, Honoraria: Novartis, BMS, Pfizer, Incyte, Celgene, Italfarmaco. Travel grants: BMS, Celgene. REC, Research support: Novartis, Pfizer, BMS. Honoraria: Novartis, Pfizer, BMS, Ariad/Incyte, Jazz, Abbvie. JEC, Research support: BMS, Novartis, Pfizer, Sun Pharma, Takeda. Honoraria: Novartis, Pfizer, Takeda. MWD, Research support: Takeda, Novartis, Pfizer, Incyte, SPARC, TetraLogic Pharmaceuticals, Blueprint. Honoraria: Blueprint, Fusion Pharma, Novartis, Sangamo, Ascentage Pharma, Adelphi, CTI, BMS, Pfizer, Takeda, Medscape, Incyte, Humana, TRM, Ariad, Galena Biopharma. FG, Research support: Novartis, Roche. Honoraria: Novartis, BMS, Celgene. HHH, Research support: Pfizer, BMS, Merck, Austrian Orphan Pharma, Nordic Cancer Union. Honoraria: Pfizer, Incyte, Austrian Orphan Pharma. TPH, Research support: Novartis, BMS, Celgene. Honoraria: Novartis, BMS, Fusion Pharma. Travel grants: Novartis. JJ, Research support: Novartis, BMS. President, Apps for Care and Science, nonprofit foundation supported by Daiichi-Sankyo, Janssen, Incyte, BMS, Servier, Jazz, Celgene. Honoraria: Abbvie, Novartis, Pfizer, Incyte. HMK, Research support: AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, Pfizer. Honoraria: AbbVie, Actinium, Agios, Amgen, Immunogen, Pfizer, Takeda. DWK, Research support: Novartis, Pfizer, BMS, Takeda, Il-Yang Co. Honoraria: Novartis, BMS, Otsuka, Il-Yang Co. RAL, Research support: Astellas, Celgene, Cellectis, Daiichi Sankyo, Novartis, Rafael Pharmaceuticals. Honoraria: Amgen, Celgene, CVS Caremark, Epizyme, Novartis, Takeda. JHL, Research support and honoraria: Novartis, BMS, Pfizer, Takeda. FXM, Research support and honoraria: Novartis. Travel grants: Celgene, Pfizer, Astra Zeneca. JM, Research support: Angelini, Pfizer, Novartis, BMS. Travel grants: Novartis. FN, Research support: Novartis, Incyte. Honoraria: Incyte biosciences, Novartis, BMS, Sun Pharma. Travel grants: Incyte biosciences, Novartis, BMS. DN, Research support: Daiichi, Honoraria: Cellectis. Travel grants: EUSA, Novartis, Amgen. FP, Research support: Novartis. Honoraria: Novartis, BMS, Pfizer, Incyte. JPR, Research support: Novartis. Honoraria: Novartis, BMS, Ariad, Amgen, Takeda, Cepheid, Bio-Rad, Adaptive, Seagen, Gilead. DR, Honoraria: BMS, Novartis, Pfizer, Incyte. JR, Honoraria: Novartis, Pfizer. GR, Research support, honoraria, and travel grants: Novartis, BMS, Incyte, Pfizer, Roche. PR, Research support: Incyte, Pfizer. Honoraria: BMS, Incyte, Pfizer, Novartis. GS, Honoraria: Novartis, BMS, Incyte, Pfizer. SiS, Honoraria: Incyte. SuS, Research support: BMS, Incyte, Novartis. Honoraria: BMS, Incyte, Novartis, Pfizer. Travel grants: BMS, Incyte, Novartis. JLS, Research support, honoraria, and travel grants: BMS, Incyte, Novartis, Pfizer. AT, Honoraria: BMS, Novartis, Pfizer, Fusion Pharma. Travel grants: BMS, Novartis, Pfizer. AZ, Research support: Novartis, Celgene, Janssen. Travel grants: Novartis. RTS, RH, none.

المصدر: Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2020, 34 (4), pp.966-984. ⟨10.1038/s41375-020-0776-2⟩
Hochhaus, A, Baccarani, M, Silver, R T, Schiffer, C, Apperley, J F, Cervantes, F, Clark, R E, Cortes, J E, Deininger, M W, Guilhot, F, Hjorth-Hansen, H, Hughes, T P, Janssen, J J W M, Kantarjian, H M, Kim, D W, Larson, R A, Lipton, J H, Mahon, F X, Mayer, J, Nicolini, F, Niederwieser, D, Pane, F, Radich, J P, Rea, D, Richter, J, Rosti, G, Rousselot, P, Saglio, G, Saußele, S, Soverini, S, Steegmann, J L, Turkina, A, Zaritskey, A & Hehlmann, R 2020, ' European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia ', Leukemia, vol. 34, no. 4, pp. 966-984 . https://doi.org/10.1038/s41375-020-0776-2
LEUKEMIA

مصطلحات موضوعية: Oncology, Cancer Research, Consensus Development Conferences as Topic, Dasatinib, Fusion Proteins, bcr-abl, Quinoline, Gene Expression, Review Article, Tyrosine-kinase inhibitor, Antineoplastic Agent, European LeukemiaNet, 0302 clinical medicine, hemic and lymphatic diseases, 0303 health sciences, Aniline Compounds, Myeloid leukemia, Disease Management, Hematology, Aniline Compound, 3. Good health, 030220 oncology & carcinogenesis, Quinolines, Imatinib Mesylate, Bosutinib, Nitrile, medicine.drug, Human, medicine.medical_specialty, medicine.drug_class, Clinical Decision-Making, Protein Kinase Inhibitor, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Targeted therapies, Life Expectancy, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Nitriles, medicine, Humans, Protein Kinase Inhibitors, Chronic myeloid leukaemia, 030304 developmental biology, Monitoring, Physiologic, business.industry, Imatinib, Survival Analysis, Discontinuation, Pyrimidines, Nilotinib, Pyrimidine, Quality of Life, business

وصف الملف: application/pdf; STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7d2e562d9ae9d3a9cb3d638c5197afe
https://hdl.handle.net/11250/2722001

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

6

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

المؤلفون: Hans Carl Hasselbalch, Tiziano Barbui, A. Maria Vannucchi, Tariq I. Mughal, Steffen Koschmieder, Heike L. Pahl, Richard T. Silver, G Barosi, Georg Jeryczynski, Jonas S. Jutzi, Francisco Cervantes, J J Kiladjian, Heinz Gisslinger, Peter Valent, Ruediger Hehlmann

المصدر: Leukemia. 30:1018-1024

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c44a9c914698ea96383a15d3c2b6637e
https://doi.org/10.1038/leu.2016.12

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

7

Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia

المؤلفون: J Hoffmann, Sabrina Inselmann, Andreas Hochhaus, Philippe Kostrewa, Ruediger Hehlmann, Kristina Sohlbach, E. Eigendorff, Martin C. Müller, Andreas Neubauer, Andreas Burchert, J Ziermann, S K Metzelder, C. Schütz, Susanne Saussele

المصدر: Leukemia. 29:1331-1335

مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Alpha interferon, Antineoplastic Agents, Interferon alpha-2, Piperazines, Cohort Studies, Young Adult, Maintenance therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Aged, Neoplasm Staging, Hematology, business.industry, Remission Induction, Interferon-alpha, Myeloid leukemia, Imatinib, Middle Aged, Prognosis, medicine.disease, Recombinant Proteins, Discontinuation, Lymphoma, Survival Rate, Leukemia, Pyrimidines, Benzamides, Immunology, Imatinib Mesylate, Drug Therapy, Combination, Female, Neoplasm Recurrence, Local, business, Follow-Up Studies, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94e895db0e101fb3be990f757f84404a
https://doi.org/10.1038/leu.2015.45

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

8

Abstracts from the 3rd Conference on Aneuploidy and Cancer: Clinical and Experimental Aspects

المؤلفون: J. Xu, N. Page, Ruediger Hehlmann, Marthe Løvf, Victor Guryev, Sarah Grasedieck, J. Stein, Paola Cavaliere, Diana C.J. Spierings, S. Bhattacharya, Caroline Jansson, Allan Bradley, Andrew L. Trinh, Zuzana Storchova, Mat Bloomfield, G. Stein, Tristan V. de Jong, Nicolaas C. Baudoin, Jonas M. SveeStrømme, H. Ding, J. Vecerova, Xue Gong, Christina Raftopoulou, Nancy Halsema, Nataliya Huleyuk, Rolf Inge Skotheim, Jordi Camps, Mathew Bloomfield, Christof Börgermann, Anita Sveen, Steven Horne, Bjarne Johannessen, Julian Swoboda, Vladimir P. Baklaushev, A. Fritz, Anders Valind, N. Donnelly, Henry H.Q. Heng, Aracelli Acevedo-Colina, Peter H. Duesberg, A. A. Stepanenko, Rainer Engers, C. Kruse, Mark D. Vincent, Yi-Hong Zhou, Lars Bullinger, Sunyoung Hwang, Fani-Marlen Roumelioti, Vladimir P. Chekhonin, R. Berezney, Martha R. Stampfer, Batoul Y. Abdallah, Guo Liu, C. Tye, David Porubsky, Jenny Karlsson, James C. Garbe, Verena Passerini, Oksana A. Kovaleva, Xinhe Huang, Andrej Schevchenko, N. Sehgal, Frank G. Rücker, Milena Dürrbaum, Karina Hoekstra-Wakker, Daniela Cimini, David Gisselsson, Ellen K. Silbergeld, Stanislav Avdieiev, Bianca Habermann, S V Andreieva, Anke van den Berg, Hans Tobias Gustafsson, Daniele Mandrioli, Jonathan R. Pollack, A. Voskanyan, Floris Foijer, Josef Dietz, Thomas Liehr, Stefan Biesterfeld, Athel Cornish-Bowden, Melissa J. Perry, Fiorella Belpoggi, Christine J. Ye, B. Stojkovicz, Lukas Vrba, Peter M. Lansdorp, Maria Colomé Tatché, Ciara O’Sullivan, Ragnhild A. Lothe, Mirjam E. Belderbos, Hinke G. Kazemier, Eveline S. J. M. de Bont, Kateryna Korets, Alfred Böcking, David Rasnick, Joshua M. Nicholson, Michelle A. Digman, Isabel Quintanilla, Sen Zhao, Yegor S. Vassetzky, Jennifer A. Marshall Graves, Bernard W. Futscher, Mark A. LaBarge, Aaron Taudt, Leonid Berynskyy, Maria Chiourea, Robert C. Dickson, Dmytro Mykytenko, Andreas M. Hoff, Noah Dephoure, C. Marcelo Aldaz, Bjorn Bakker, Christian Klose, Sarantis Gagos, Alice Fabarius, Eduardo M. Torres, Kimberly Soto

المصدر: Molecular Cytogenetics. 10

مصطلحات موضوعية: Genetics, Philosophy, Biochemistry (medical), Molecular Medicine, Theology, Molecular Biology, Biochemistry, Genetics (clinical), 3. Good health

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::0518216992689d40e0acd572b7e762ce
https://doi.org/10.1186/s13039-017-0320-x

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

9

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice : SIMPLICITY

المؤلفون: Pascale Cony-Makhoul, Carlo Gambacorti-Passerini, Elza Lomaia, Ruediger Hehlmann, Bengt Simonsson, Michael J. Mauro, Aart Beeker, Mauricette Michallet, Eduardo Olavarria, Stuart L. Goldberg, Richard M. Hansen, Elisabetta Abruzzese, David Andorsky, Aimee Foreman, Jorge E. Cortes, Teresa Zyczynski, H. Jean Khoury, Ron Paquette

المساهمون: Goldberg, S, Cortes, J, Gambacorti-Passerini, C, Hehlmann, R, Khoury, H, Michallet, M, Paquette, R, Simonsson, B, Zyczynski, T, Foreman, A, Abruzzese, E, Andorsky, D, Beeker, A, Cony-Makhoul, P, Hansen, R, Lomaia, E, Olavarria, E, Mauro, M

المصدر: American Journal of Hematology

مصطلحات موضوعية: Oncology, Adult, Male, United State, medicine.medical_specialty, Pediatrics, Myeloid, media_common.quotation_subject, Biopsy, Protein Kinase Inhibitor, Comorbidity, Follow-Up Studie, 03 medical and health sciences, 0302 clinical medicine, Bone Marrow, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Routine clinical practice, Simplicity, Hematologi, Practice Patterns, Physicians', Protein Kinase Inhibitors, Selection (genetic algorithm), Research Articles, In Situ Hybridization, Fluorescence, media_common, Aged, Hematology, business.industry, Myeloid leukemia, Middle Aged, medicine.disease, United States, Europe, Leukemia, medicine.anatomical_structure, Treatment Outcome, 030220 oncology & carcinogenesis, Leukemia, Myeloid, Chronic-Phase, Female, Bone marrow, business, 030215 immunology, Follow-Up Studies, Research Article, Human

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22ad2e6a3c4d932c21654f5abea0ec46
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-339738

10

MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure

المؤلفون: Dominik Wolf, Purkayastha D, Martin C. Müller, Richard C. Woodman, Mridul Agrawal, Alice Fabarius, Susanne Saussele, Andreas Hochhaus, Ruediger Hehlmann, Philipp Erben, Thomas Ernst, Wolf-K. Hofmann, Benjamin Hanfstein

المصدر: Leukemia. 28:1478-1485

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Fusion Proteins, bcr-abl, Gene Expression, Gastroenterology, Piperazines, hemic and lymphatic diseases, Internal medicine, Humans, Medicine, ATP Binding Cassette Transporter, Subfamily B, Member 1, Treatment Failure, Protein Kinase Inhibitors, neoplasms, IC50, Aged, Neoplasm Staging, P-glycoprotein, Aged, 80 and over, biology, business.industry, Wild type, Myeloid leukemia, Imatinib, Hematology, Middle Aged, Prognosis, Pyrimidines, Treatment Outcome, Imatinib mesylate, Oncology, Nilotinib, Gene Knockdown Techniques, Benzamides, Leukemia, Myeloid, Chronic-Phase, Mutation, Immunology, Imatinib Mesylate, biology.protein, Female, RNA Interference, business, Tyrosine kinase, Follow-Up Studies, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec5279fa8c25c638f4aa5342f684e3bb
https://doi.org/10.1038/leu.2014.6

Find this article in full text from ProQuest

تنقيح النتائج